Merck (1MRKX) Stock Overview
Operates as a healthcare company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
1MRKX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Merck & Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$72.60 |
| 52 Week High | US$119.20 |
| 52 Week Low | US$65.40 |
| Beta | 0.40 |
| 1 Month Change | 7.56% |
| 3 Month Change | -2.29% |
| 1 Year Change | -38.16% |
| 3 Year Change | -15.78% |
| 5 Year Change | 2.25% |
| Change since IPO | -7.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1MRKX | IT Pharmaceuticals | IT Market | |
|---|---|---|---|
| 7D | 7.1% | 4.5% | 1.6% |
| 1Y | -38.2% | -19.2% | 19.8% |
Return vs Industry: 1MRKX underperformed the Italian Pharmaceuticals industry which returned -18.7% over the past year.
Return vs Market: 1MRKX underperformed the Italian Market which returned 19.1% over the past year.
Price Volatility
| 1MRKX volatility | |
|---|---|
| 1MRKX Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 8.0% |
| 10% least volatile stocks in IT Market | 2.6% |
Stable Share Price: 1MRKX has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1MRKX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 74,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Merck & Co., Inc. Fundamentals Summary
| 1MRKX fundamental statistics | |
|---|---|
| Market cap | €183.50b |
| Earnings (TTM) | €15.04b |
| Revenue (TTM) | €55.15b |
Is 1MRKX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1MRKX income statement (TTM) | |
|---|---|
| Revenue | US$63.92b |
| Cost of Revenue | US$14.66b |
| Gross Profit | US$49.27b |
| Other Expenses | US$31.83b |
| Earnings | US$17.43b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 29, 2025
| Earnings per share (EPS) | 6.94 |
| Gross Margin | 77.07% |
| Net Profit Margin | 27.27% |
| Debt/Equity Ratio | 72.0% |
How did 1MRKX perform over the long term?
See historical performance and comparisonDividends
Does 1MRKX pay a reliable dividends?
See 1MRKX dividend history and benchmarks| Merck dividend dates | |
|---|---|
| Ex Dividend Date | Sep 12 2025 |
| Dividend Pay Date | Oct 07 2025 |
| Days until Ex dividend | 44 days |
| Days until Dividend pay date | 69 days |
Does 1MRKX pay a reliable dividends?
See 1MRKX dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/28 13:20 |
| End of Day Share Price | 2025/07/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Merck & Co., Inc. is covered by 57 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Fabrizio Spagna | Axia Financial Research |
| Charles Butler | Barclays |